Un estudio para investigar la eficacia y seguridad de anifrolumab en adultos con lupus eritematoso cutáneo crónico y/o subagudo (LAVENDER)
Un estudio de fase III multicéntrico, aleatorizado, doble ciego, controladora con placebo para evaluar la eficacia y seguridad de anifrolumab en adultos con lupus eritematoso cutáneo crónico y/o subagudo que son refractarios y/o intolerantes al tratamiento antipalúdico
This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with chronic and/or subacute cutaneous lupus erythematosus (CLE).
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
This is a multicenter, randomized, double-blind, placebo-controlled, Phase III study to evaluate the efficacy and safety of anifrolumab in adults with chronic and/or subacute CLE who are refractory and/or intolerant to antimalarial therapy. The study has a randomized, 24-week double-blind, placebo-controlled study period (Week 0 to Week 23), to evaluate the efficacy and safety of anifrolumab. The double-blind study period will be followed by an open-label, uncontrolled treatment period in which all participants will receive treatment with anifrolumab from Week 24 to Week 51. After the open-label treatment period, participants will enter a 12-week Safety Follow-up Period.
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Berlin, Alemania, 10117
- Research Site
-
Bochum, Alemania, 44791
- Research Site
-
Dresden, Alemania, 01307
- Research Site
-
Erlangen, Alemania, 91054
- Research Site
-
Essen, Alemania, 45147
- Research Site
-
Freiburg im Breisgau, Alemania, 79104
- Research Site
-
Hanover, Alemania, 30625
- Research Site
-
Kiel, Alemania, 24105
- Research Site
-
Leipzig, Alemania, 04103
- Research Site
-
Mainz, Alemania, 55131
- Research Site
-
Marburg, Alemania, 35043
- Research Site
-
Regensburg, Alemania, 93053
- Research Site
-
Wuppertal, Alemania, 42283
- Research Site
-
-
-
-
-
Ciudad de Buenos Aires, Argentina, 1221
- Research Site
-
Córdoba, Argentina, 5000
- Research Site
-
Córdoba, Argentina, X5004BAL
- Research Site
-
Quilmes, Argentina, 1878
- Research Site
-
San Miguel, Argentina, 1663
- Research Site
-
-
-
-
-
Kogarah, Australia, 3168
- Research Site
-
Melbourne, Australia, 3004
- Research Site
-
Mitcham, Australia, 3132
- Research Site
-
Westmead, Australia, 2145
- Research Site
-
Woolloongabba, Australia, 04102
- Research Site
-
-
-
-
-
Graz, Austria, 8036
- Research Site
-
Innsbruck, Austria, 6020
- Research Site
-
Linz, Austria, 4020
- Research Site
-
Vienna, Austria, 1130
- Research Site
-
-
-
-
-
Belo Horizonte, Brasil, 30150-221
- Research Site
-
Porto Alegre, Brasil, 90035903
- Research Site
-
Rio de Janeiro, Brasil, 22470-220
- Research Site
-
Salvador, Brasil, 40150-150
- Research Site
-
São Paulo, Brasil, 05403-000
- Research Site
-
-
-
-
-
Sofia, Bulgaria, 1784
- Research Site
-
Sofia, Bulgaria, 1463
- Research Site
-
Sofia, Bulgaria, 1528
- Research Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V5Z 1M9
- Research Site
-
-
Ontario
-
Hamilton, Ontario, Canadá, L8N 3Z5
- Research Site
-
Toronto, Ontario, Canadá, M5T 2S8
- Research Site
-
-
-
-
-
Osorno, Chile, 200025
- Research Site
-
Santiago, Chile, 7500571
- Research Site
-
Santiago, Chile, 130021
- Research Site
-
-
-
-
-
Barranquilla, Colombia, 080020
- Research Site
-
Bogotá, Colombia, 110221
- Research Site
-
-
-
-
-
Seoul, Corea del Sur, 03080
- Research Site
-
Seoul, Corea del Sur, 06591
- Research Site
-
Seoul, Corea del Sur, 06973
- Research Site
-
-
-
-
-
Aarhus, Dinamarca, 641-8510
- Research Site
-
Copenhagen, Dinamarca, 2100
- Research Site
-
-
-
-
-
Košice, Eslovaquia, 04001
- Research Site
-
Piešťany, Eslovaquia, 92101
- Research Site
-
-
-
-
-
Barcelona, España, 8035
- Research Site
-
Barcelona, España, 08025
- Research Site
-
Castellon, España, 12004
- Research Site
-
Granada, España, 18012
- Research Site
-
L'Hospitalet de Llobregat, España, 08907
- Research Site
-
Las Palmas de Gran Canaria, España, 35010
- Research Site
-
Madrid, España, 28034
- Research Site
-
Madrid, España, 28041
- Research Site
-
Madrid, España, 28040
- Research Site
-
Madrid, España, 28006
- Research Site
-
Majadahonda, España, 28222
- Research Site
-
Salamanca, España, 37007
- Research Site
-
Seville, España, 41014
- Research Site
-
Valencia, España, 46014
- Research Site
-
Valencia, España, 46017
- Research Site
-
Vigo, España, 36200
- Research Site
-
-
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85028
- Research Site
-
-
California
-
Covina, California, Estados Unidos, 91722
- Research Site
-
La Jolla, California, Estados Unidos, 92037
- Research Site
-
Los Angeles, California, Estados Unidos, 90045
- Research Site
-
Los Angeles, California, Estados Unidos, 90089
- Research Site
-
Orange, California, Estados Unidos, 92868
- Research Site
-
San Francisco, California, Estados Unidos, 94143
- Research Site
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Research Site
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06519
- Research Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20037
- Research Site
-
-
Florida
-
Fort Lauderdale, Florida, Estados Unidos, 33309
- Research Site
-
Miami, Florida, Estados Unidos, 33174
- Research Site
-
Plantation, Florida, Estados Unidos, 33324
- Research Site
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60637
- Research Site
-
Chicago, Illinois, Estados Unidos, 60611
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Research Site
-
Boston, Massachusetts, Estados Unidos, 02115-5817
- Research Site
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- Research Site
-
Bloomfield Hills, Michigan, Estados Unidos, 48302
- Research Site
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68198-5885
- Research Site
-
-
New York
-
New York, New York, Estados Unidos, 10028
- Research Site
-
Rochester, New York, Estados Unidos, 14642
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28207
- Research Site
-
Statesville, North Carolina, Estados Unidos, 28625
- Research Site
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44195
- Research Site
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Research Site
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02903
- Research Site
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29425
- Research Site
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390-8843
- Research Site
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22903
- Research Site
-
Roanoke, Virginia, Estados Unidos, 24016
- Research Site
-
-
-
-
-
Iloilo City, Filipinas, 5000
- Research Site
-
Lipa, Filipinas, 4217
- Research Site
-
Manila, Filipinas, 1000
- Research Site
-
-
-
-
-
Bois-Guillaume, Francia, 76031
- Research Site
-
Dijon, Francia, 21000
- Research Site
-
Lyon, Francia, 69437
- Research Site
-
Montivilliers, Francia, 76290
- Research Site
-
Nantes, Francia, 44000
- Research Site
-
Paris, Francia, 75010
- Research Site
-
Paris, Francia, 75014
- Research Site
-
Paris, Francia, 75013
- Research Site
-
Paris, Francia, 75970
- Research Site
-
Poitiers, Francia, 86000, FR
- Research Site
-
Toulouse, Francia, 31059
- Research Site
-
-
-
-
-
Athens, Grecia, 12462
- Research Site
-
Athens, Grecia, 16121
- Research Site
-
-
-
-
-
Brescia, Italia, 25123
- Research Site
-
Cona, Italia, 44124
- Research Site
-
Florence, Italia, 50121
- Research Site
-
Milan, Italia, 20132
- Research Site
-
Naples, Italia, 80138
- Research Site
-
Reggio Emilia, Italia, 42123
- Research Site
-
Roma, Italia, 00144
- Research Site
-
Rome, Italia, 00168
- Research Site
-
-
-
-
-
Chūōku, Japón, 104-8560
- Research Site
-
Fukuoka, Japón, 812-8582
- Research Site
-
Kanazawa, Japón, 920-8641
- Research Site
-
Kita-gun, Japón, 761-0793
- Research Site
-
Nagoya, Japón, 457-8510
- Research Site
-
Nagoya, Japón, 467-8602
- Research Site
-
Wakayama, Japón, 641-8510
- Research Site
-
Yokohama, Japón, 232-0024
- Research Site
-
tabashi City, Japón, 173-8606
- Research Site
-
-
-
-
-
Guadalajara, México, 44340
- Research Site
-
Guadalajara, México, 44610
- Research Site
-
Mexico City, México, 07760
- Research Site
-
Veracruz, México, 91910
- Research Site
-
-
-
-
-
Papatoetoe, Nueva Zelanda, 2025
- Research Site
-
-
-
-
-
Breda, Países Bajos, 4818 CK
- Research Site
-
Rotterdam, Países Bajos, 3015 GD
- Research Site
-
-
-
-
-
Katowice, Polonia, 40-851
- Research Site
-
Kielce, Polonia, 25-316
- Research Site
-
Ossy, Polonia, 40-027
- Research Site
-
Rzeszów, Polonia, 35-055
- Research Site
-
Warsaw, Polonia, 02-637
- Research Site
-
-
-
-
-
Changchun, Porcelana, 130021
- Research Site
-
Changsha, Porcelana, 410011
- Research Site
-
Chengdu, Porcelana, 610021
- Research Site
-
Chongqing, Porcelana, 400016
- Research Site
-
Dongguan, Porcelana, 523059
- Research Site
-
Guangzhou, Porcelana, 510120
- Research Site
-
Heilongjiang, Porcelana, 150086
- Research Site
-
Jinan, Porcelana, 250022
- Research Site
-
Shanghai, Porcelana, 200025
- Research Site
-
Shanghai, Porcelana, 200443
- Research Site
-
Shenzhen, Porcelana, 518053
- Research Site
-
Shenzhen, Porcelana, 518020
- Research Site
-
Shenzhen, Porcelana, 518052
- Research Site
-
Zhuzhou, Porcelana, 412007
- Research Site
-
Ürümqi, Porcelana, CN-830004
- Research Site
-
-
-
-
-
Braga, Portugal, 4710-243
- Research Site
-
Lisbon, Portugal, 1649-035
- Research Site
-
Porto, Portugal, 4099-001
- Research Site
-
-
-
-
-
Cambridge, Reino Unido, CB2 0QQ
- Research Site
-
Leeds, Reino Unido, LS2 9JT
- Research Site
-
London, Reino Unido, NW1 2PG
- Research Site
-
London, Reino Unido, SE5 9RS
- Research Site
-
London, Reino Unido, SE1 7EH
- Research Site
-
London, Reino Unido, NW3 2QG
- Research Site
-
Newcastle upon Tyne, Reino Unido, NE1 4LP
- Research Site
-
-
-
-
-
Bucharest, Rumania, 020125
- Research Site
-
Iași, Rumania, 700291
- Research Site
-
-
-
-
-
Belgrade, Serbia, 11000
- Research Site
-
Kragujevac, Serbia, 34000
- Research Site
-
-
-
-
-
Cape Town, Sudáfrica, 7500
- Research Site
-
Johannesburg, Sudáfrica, 2193
- Research Site
-
-
-
-
-
Bangkok, Tailandia, 10330
- Research Site
-
Bangkok, Tailandia, 10700
- Research Site
-
Hat Yai, Tailandia, 90110
- Research Site
-
Khlong Luang, Tailandia, 12120
- Research Site
-
Khon Kaen, Tailandia, 40002
- Research Site
-
-
-
-
-
Kaohsiung City, Taiwán, 83301
- Research Site
-
Taichung, Taiwán, 404
- Research Site
-
Taipei, Taiwán, 10449
- Research Site
-
-
-
-
-
Cordaleo, Turquía (Türkiye), 35575
- Research Site
-
Istanbul, Turquía (Türkiye), 34098
- Research Site
-
Kayseri, Turquía (Türkiye), 38039
- Research Site
-
Samsun, Turquía (Türkiye), 55270
- Research Site
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Key inclusion criteria:
-
Participants must have a confirmed diagnosis of CLE. Diagnosis must be clinically and histologically confirmed with the following:
- CLASI-A total score ≥ 10 points at Screening and confirmed at randomization.
- Inadequate response or intolerant to antimalarial therapy.
-
Participants should have no medical history or signs or symptoms of active or prior tuberculosis infection (TB) and the same should reflect in chest radiograph or a chest CT scan result.
-
Contraceptive use by males and females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Key exclusion criteria:
- History or evidence of suicidal ideation.
- Severe or life-threatening Systemic lupus erythematosus (SLE).
- Active SLE or Sjögren's Syndrome.
- Any active skin conditions other than CLE that may interfere with the study.
- History of, or current diagnosis of, catastrophic antiphospholipid syndrome (APS).
- History of recurrent infection requiring hospitalization and IV antibiotics.
- COVID-19 infection.
- Any history of an anaphylactic reaction to human proteins, or monoclonal antibodies.
- At screening, if participants do not meet the eligibility criteria assessed based on laboratory test results e.g tests for total bilirubin, serum creatinine etc.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Anifrolumab
Participants will receive anifrolumab as a SC injection from Week 0/Day 1 up to Week 51. |
Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS). |
|
Comparador de placebos: Placebo
Participants will receive placebo as a SC injection from Week 0/Day 1 up to Week 23. From Week 24 the participants will receive anifrolumab up to and including Week 51. |
Matching placebo solution for injection in aPFS. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of participants with a 70% reduction relative to baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) score
Periodo de tiempo: At Week 24
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. It consists of 2 separate scores: i) activity of the disease, and ii) measure of damage. The CLASI instrument will be used at each study visit to capture individual skin manifestation scores. CLASI-70 responder (Yes/No) is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. |
At Week 24
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from baseline in total CLASI-A score
Periodo de tiempo: At Week 24
|
The CLASI-A is a validated index used for assessing the cutaneous lesions of SLE. |
At Week 24
|
|
Number of participants with CLASI-70 response
Periodo de tiempo: At Week 12
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. |
At Week 12
|
|
Number of participants with ≥ 7-point reduction from baseline in CLASI-A total score
Periodo de tiempo: At Week 12
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. A 7-point reduction CLASI-A is established as clinically meaningful improvement in disease for CLE and as being impactful for patients. |
At Week 12
|
|
Number of participants with CLASI-50 response
Periodo de tiempo: At Week 12 and Week 24
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-50 responder is defined as a responder (yes/no) is defined as a participant who achieves at least a 50% reduction relative to baseline in CLASI-A score. Otherwise, the participant is a non-responder. |
At Week 12 and Week 24
|
|
Number of participants who are sustained CLASI-70 responders
Periodo de tiempo: Up to Week 52
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. Amongst participants randomized to anifrolumab, the number of participants who maintained a CLASI-70 response from Week 24 up to Week 52 will be evaluated. |
Up to Week 52
|
|
Serum trough (pre-dose) concentrations of anifrolumab
Periodo de tiempo: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)
|
The Ctrough of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)
|
|
Number of participants with positive antidrug antibody
Periodo de tiempo: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)
|
The immunogenicity of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)
|
|
Percent change from baseline in suppression of the Interferon 21-gene
Periodo de tiempo: Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)
|
The pharmacodynamics of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)
|
|
Change from baseline in Skindex-29+3 Symptom domain scores
Periodo de tiempo: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. The instrument consists of 33 items, which are used to calculate 4 domains: Symptoms (7 items), Emotions (10 items), Functioning (12 items), and Lupus-specific (3 items). The remaining item asks the participants to rate how often they worry about side effects from treatment; however, this item is not used to calculate the domain scores. The response options are on a 5-point verbal rating scale, ranging from 1 (Never) to 5 (All the time). The instrument has a recall period of the previous 4 weeks. Each domain score ranges from 0 to 100 points, with higher scores indicating worse health-related quality of life. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Emotion domain scores
Periodo de tiempo: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Function domain scores
Periodo de tiempo: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Lupus-Specific domain scores
Periodo de tiempo: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Total score
Periodo de tiempo: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Time from IP start date to CLASI-70 response.
Periodo de tiempo: From Week 0/Day 1 up to Week 24
|
To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE. |
From Week 0/Day 1 up to Week 24
|
|
Time from IP start date to CLASI-50 response.
Periodo de tiempo: From Week 0/Day 1 up to Week 24
|
To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE. |
From Week 0/Day 1 up to Week 24
|
Otras medidas de resultado
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of participants with adverse events
Periodo de tiempo: Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)
|
To evaluate the safety and tolerability of anifrolumab compared with placebo in participants with CLE. |
Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- D346BC00001
- 2021-003698-70 (Número EudraCT)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Marco de tiempo para compartir IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Criterios de acceso compartido de IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .